Chartwell Partners is pleased to announce the recruitment of Esin Kosal, PhD as SVP, Regulatory Affairs for EryDel SpA, a global biotechnology company utilizing its proprietary red blood cell drug delivery technology to encapsulate small and large molecules into a patient’s own red blood cells which are then reinfused into that patient in a fast, automatic bedside procedure. EryDel’s most advanced product candidate, EryDex, is being evaluated in a pivotal Phase 3 study, ATTeST, for the treatment of patients with Ataxia Telangiectasia (AT), a rare neurodegenerative autosomal recessive disorder for which no established therapy is currently available. Dr. Kosal brings to EryDel over 20 years of global regulatory affairs experience, including substantial work in rare and neurological diseases. She joins EryDel from Mitsubishi Tanabe Pharmaceuticals.
For more information, please visit https://www.erydel.com/uplPdf/erydel-appoints-dr-esin-kosal-phdas-senior-vice-president-global-regulatory-affairs.pdf
- Sara S. Hagar
- Contact Card